Page last updated: 2024-12-10

5-oxo-6,8,11,14-eicosatetraenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-oxo-6,8,11,14-eicosatetraenoic acid: RN given is for cpd without isomeric designation; an arachidonate metabolite which stimulates neutrophils to mobilize Ca and promotes PMN degranulation responses [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-ketoeicosatetraenoic acid: a nonenzymatic rearrangement product of leukotriene A4; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-oxo-ETE : An oxoicosatetraenoic acid having a 5-oxo group; and (6E)-, (8Z), (11Z)- and (14Z)-double bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5353355
SCHEMBL ID2785074
MeSH IDM0215798
PubMed CID5283159
CHEMBL ID18028
CHEBI ID52449
SCHEMBL ID139762
MeSH IDM0215798

Synonyms (54)

Synonym
5-keto-6,8,11,14-eicosatetraenoic acid
126432-17-5
5-oxo-6,8,11,14-eicosatetraenoic acid
5-kete
5-oxo-6,8,11,14-ete
5-oxo-eicosatetraenoate
5-oxoete
6,8,11,14-eicosatetraenoic acid, 5-oxo-
AKOS015911180
SCHEMBL2785074
J-001548
Q50318269
5-ketoeicosa-6e,8z,11z,14e-tetraenoic acid
gtpl3391
5-oxo-ete
LMFA03060011
5-oxo-6e,8z,11z,14z-eicosatetraenoic acid
IDI1_033923
BSPBIO_001453
5-oxoicosatetraenoic acid
(6e,8z,11z,14z)-5-oxoicosa-6,8,11,14-tetraenoic acid
5-oxoeicosatetraenoic acid
NCGC00161269-02
NCGC00161269-01
NCGC00161269-03
HMS1989I15
5-ketoeicosatetraenoic acid
5-oxo-6(e),8(z),11(z),14(z)-eicosatetraenoic acid
5-oxo, 6t,8c,11c,14c-20:4
5-keto-ete
CHEBI:52449 ,
CHEMBL18028 ,
BML1-D12
HMS1361I15
HMS1791I15
ete-5-oxo
bdbm50024458
6,8,11,14-eicosatetraenoicacid, 5-oxo-, (6e,8z,11z,14z)-
106154-18-1
[3h]5-oxo-ete
gtpl3416
[3h]-5-oxo-ete
SCHEMBL139762
MEASLHGILYBXFO-XTDASVJISA-N
HMS3402I15
6,8,11,14-eicosatetraenoicacid,5-oxo-,(6e,8z,11z,14z)-
5-oxo-eicosatetraenoic acid
5-keto-6,8,11,14-eicosatetraenoate
5-oxo-6,8,11,14-eicosatetraenoate
5-ketoeicosa-6,8,11,14-tetraenoic acid
Q25323762
SR-01000946916-1
sr-01000946916
AKOS040755743

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies revealed that 230 appears rapidly in the blood following oral administration."( Pharmacokinetics and Metabolism of Selective Oxoeicosanoid (OXE) Receptor Antagonists and Their Effects on 5-Oxo-6,8,11,14-eicosatetraenoic Acid (5-Oxo-ETE)-Induced Granulocyte Activation in Monkeys.
Chourey, S; Cossette, C; Gore, V; Gravel, S; Nagendra Reddy, C; Powell, WS; Rokach, J; Slobodchikova, I; Vuckovic, D; Ye, Q, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
immunomodulatorBiologically active substance whose activity affects or plays a role in the functioning of the immune system.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oxoicosatetraenoic acidAny C20 polyunsaturated fatty acid having four double bonds and at least one oxo group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (56)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of 5-eicosatetraenoic acids615
Signaling Pathways1269117
Signaling by GPCR24955
GPCR ligand binding19339
Class A/1 (Rhodopsin-like receptors)16136
Eicosanoid ligand-binding receptors117
GPCR downstream signalling17252
G alpha (i) signalling events8741
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Eicosanoid metabolism via lipooxygenases (LOX)040
Arachidonic acid (AA, ARA) oxylipin metabolism076
Eicosanoid metabolism via lipoxygenases (LOX)040
Arachidonic acid metabolism via LOX (Lipooxygenase) pathway033

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)IC50 (µMol)100.00000.03201.46494.8000AID1179716
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)18.00000.00462.018210.0000AID6849
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)25.00000.11003.26419.0330AID1179717
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)IC50 (µMol)25.00000.04002.099810.0000AID1179715
Polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)IC50 (µMol)15.00000.10002.452310.0000AID1179714
Oxoeicosanoid receptor 1Homo sapiens (human)IC50 (µMol)0.00300.00301.41722.0000AID590219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Oxoeicosanoid receptor 1Homo sapiens (human)EC50 (µMol)0.11350.00700.09430.2200AID1497846; AID579486
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
ossificationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
negative regulation of adaptive immune responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylethanolamine biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of cell-substrate adhesionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
bone mineralizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of actin filament polymerizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to endoplasmic reticulum stressPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to interleukin-13Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
wound healingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
apoptotic cell clearancePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to calcium ionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of engulfment of apoptotic cellPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of muscle cell apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
unsaturated fatty acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
superoxide anion generationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
establishment of skin barrierPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of platelet aggregationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin B4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayOxoeicosanoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayOxoeicosanoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin-epoxide hydrolase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
G protein-coupled receptor activityOxoeicosanoid receptor 1Homo sapiens (human)
protein bindingOxoeicosanoid receptor 1Homo sapiens (human)
5-oxo-6E,8Z,11Z,14Z-icosatetraenoic acid bindingOxoeicosanoid receptor 1Homo sapiens (human)
5-hydroxy-6E,8Z,11Z,14Z-icosatetraenoic acid bindingOxoeicosanoid receptor 1Homo sapiens (human)
5(S)-hydroxyperoxy-6E,8Z,11Z,14Z-icosatetraenoic acid bindingOxoeicosanoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid dropletPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmic side of plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
plasma membraneOxoeicosanoid receptor 1Homo sapiens (human)
plasma membraneOxoeicosanoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346064Human OXE receptor (Leukotriene receptors)2008The Journal of pharmacology and experimental therapeutics, May, Volume: 325, Issue:2
Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity.
AID1346064Human OXE receptor (Leukotriene receptors)1995The Journal of biological chemistry, Jun-23, Volume: 270, Issue:25
5-Oxo-eicosanoids are potent eosinophil chemotactic factors. Functional characterization and structural requirements.
AID1346064Human OXE receptor (Leukotriene receptors)2009Prostaglandins & other lipid mediators, Sep, Volume: 89, Issue:3-4
5-Oxo-ETE and the OXE receptor.
AID1346064Human OXE receptor (Leukotriene receptors)1998The Journal of biological chemistry, Dec-04, Volume: 273, Issue:49
Receptors for the 5-oxo class of eicosanoids in neutrophils.
AID1346064Human OXE receptor (Leukotriene receptors)1992The Journal of biological chemistry, Sep-25, Volume: 267, Issue:27
Metabolism of 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes.
AID590146Agonist activity at 5-oxo-ETE receptor in indo-1-labeled human neutrophils assessed as stimulation intracellular calcium level at 10 nM followed by vehicle addition in presence of digitonin added at 3.5 mins2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
C20-trifluoro-5-oxo-ETE: a metabolically stable 5-oxo-ETE derivative.
AID579486Agonist activity at 5-oxo-ETE receptor in human neutrophils assessed as stimulation of ca2+ mobilization2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
5-oxo-15-HETE: total synthesis and bioactivity.
AID1179719Activity of human leukocyte 5-lipoxygenase by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes.
AID1179713Inhibition of human leukocyte 5-lipoxygenase by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes.
AID1179716Inhibition of human reticulocyte 15-lipoxygenase-2 by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes.
AID1179715Inhibition of human reticulocyte 15-lipoxygenase-1 by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes.
AID1179714Inhibition of human platelet 12-lipoxygenase by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes.
AID6849In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid analogues.
AID1179718Inhibition of soybean 15-lipoxygenase-1 by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes.
AID1179717Inhibition of rabbit reticulocyte 15-LOX by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes.
AID590219Desensitization of 5-oxo-ETE receptor in indo-1-labeled human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
C20-trifluoro-5-oxo-ETE: a metabolically stable 5-oxo-ETE derivative.
AID1497846Agonist activity at human PK-tagged OXER1 expressed in CHOK1 cells assessed as EA-tagged beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis, molecular modelling studies and biological evaluation of new oxoeicosanoid receptor 1 agonists.
AID590148Induction of intracellular calcium level in indo-1-labeled human neutrophils cells assessed as calcium mobilization2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
C20-trifluoro-5-oxo-ETE: a metabolically stable 5-oxo-ETE derivative.
AID1497847Agonist activity at human PK-tagged OXER1 expressed in CHOK1 cells assessed as EA-tagged beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation assay relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis, molecular modelling studies and biological evaluation of new oxoeicosanoid receptor 1 agonists.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (107)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.93)18.7374
1990's27 (25.23)18.2507
2000's37 (34.58)29.6817
2010's32 (29.91)24.3611
2020's10 (9.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.27%)5.53%
Trials0 (0.00%)5.53%
Reviews6 (6.82%)6.00%
Reviews2 (8.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other80 (90.91%)84.16%
Other23 (92.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]